Loading stock data…
AVXL
$2.54-0.08 (-3.05%)
After Hours$2.54+0.00 (+0.00%)· Last close Jun 9
Anavex Life Sciences Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anavex Life Sciences Corp. in the Healthcare sector is trading at $2.54. Wall Street consensus targets $20.00 (1 analysts), implying a +687.4% move over the next 12 months. The stock is currently near its 52-week low of $2.48, remaining 51.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +687.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.54
Potential Downside
0%
Whystock Fair Value$2.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$20.00+687.4%
Range$20.00 – $20.00
Fundamentals
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.55%
Volume
Today's trading volume
857,670
Recent News
Penny Stocks To Watch In May 2026
The market is up 1.8% over the last week and has climbed 28% over the past year, with earnings forecast to grow by 17% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. We've selected three examples of penny stocks that combine balance sheet strength with potential for outsized gains, giving investors a chance to discover hidden value in quality...
Exploring High Growth Tech Stocks In The US Market May 2026
The United States market has shown robust performance, rising 1.3% over the last week and 28% over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential to capitalize on these favorable conditions.
CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus
Anavex appointed former clinical development executive Terrie Kellmeyer as interim CEO following the departure of longtime chief executive Christopher Missling, while also signaling a delay in its quarterly SEC filing. Key Investor TakeawaysAnavex Life Sciences Corp.
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
Exploring Three High Growth Tech Stocks In The US Market
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth expectations, identifying high growth tech stocks that align with these trends can be crucial for investors seeking opportunities in a dynamic sector.